Related Experiment Video

Updated: Jun 20, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.3K

The SIRT7-nucleolus connection in cancer: ARF enters the fray

Shahriar Tarighi1, Poonam Kumari1, Alejandro Vaquero2

  • 1Department of Cardiac Development and Remodeling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.

Molecular & Cellular Oncology
|July 22, 2024
PubMed

Insights

The nucleolar enzyme sirtuin 7 (SIRT7) drives cancer growth by destabilizing a key protein. Targeting SIRT7 in the nucleolus may offer new anti-cancer therapies.

Area of Science:

  • Molecular biology
  • Cancer research
  • Biochemistry

Background:

  • Sirtuin 7 (SIRT7) is a nucleolar enzyme implicated in cancer progression.
  • Ribosome biosynthesis is a known pathway influenced by SIRT7.
  • The precise mechanisms by which SIRT7 promotes cancer are under investigation.

Purpose of the Study:

  • To investigate the role of nucleolar sirtuin 7 (SIRT7) in cancer progression.
  • To identify novel molecular targets for anti-cancer therapies.
  • To elucidate the interaction between SIRT7 and the cyclin dependent kinase inhibitor 2A (CDKN2A/ARF) pathway.

Main Methods:

  • Biochemical assays to study protein stability.
  • Cellular localization studies within the nucleolus.
  • Analysis of SIRT7's impact on CDKN2A/ARF expression and function.

Main Results:

  • SIRT7 was found to destabilize the cyclin dependent kinase inhibitor 2A (CDKN2A, also known as ARF).
  • This destabilization occurs within the nucleolus, a key cellular compartment.
  • SIRT7's action on CDKN2A/ARF contributes to cancer progression.

Conclusions:

  • Nucleolar SIRT7 plays a significant role in promoting cancer by regulating CDKN2A/ARF stability.
  • Targeting nucleolar SIRT7 presents a promising strategy for developing novel anti-cancer treatments.
  • Further research into SIRT7 inhibition could lead to new therapeutic avenues.
Keywords:
SIRT7Sirtuin 7cancernucleolus

More Related Videos

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells11:11

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells

Published on: April 25, 2018

8.0K
Monitoring Protein-RNA Interaction Dynamics In Vivo at High Temporal Resolution Using χCRAC09:15

Monitoring Protein-RNA Interaction Dynamics In Vivo at High Temporal Resolution Using χCRAC

Published on: May 9, 2020

5.0K

Related Concept Videos

The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Regulation of Nuclear Protein Sorting01:45

Regulation of Nuclear Protein Sorting

Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
2.4K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.0K